Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus cyclophosphamide and vinorelbine for relapsed/recurrent/refractory DSRCT in pediatric and young adult patients
NL-OMON52509Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ramucirumab, cyclophosphamide and vinorelbine in desmoplastic small round cell tumor (DSRCT), sponsored by Eli Lilly and Company. Planned start Feb 2020; status: withdrawn.
02
Drugs
ramucirumabcyclophosphamidevinorelbine
03
Conditions
desmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NL-OMON52509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52509.